Edwards Lifesciences Corporation $EW Shares Purchased by Csenge Advisory Group

Csenge Advisory Group grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 127.8% during the third quarter, Holdings Channel reports. The firm owned 14,437 shares of the medical research company’s stock after acquiring an additional 8,099 shares during the quarter. Csenge Advisory Group’s holdings in Edwards Lifesciences were worth $1,246,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in Edwards Lifesciences in the second quarter valued at approximately $1,274,082,000. Bank of America Corp DE acquired a new position in Edwards Lifesciences in the second quarter valued at approximately $605,397,000. Deutsche Bank AG acquired a new position in Edwards Lifesciences in the second quarter valued at approximately $516,552,000. Finally, Legal & General Group Plc bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $389,089,000. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 53,945 shares of company stock valued at $5,498,306 over the last ninety days. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on EW shares. UBS Group raised their price objective on shares of Edwards Lifesciences from $110.00 to $118.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. TD Cowen boosted their target price on shares of Edwards Lifesciences from $117.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, November 5th. BTIG Research increased their target price on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Finally, Evercore restated an “outperform” rating on shares of Edwards Lifesciences in a report on Friday, October 23rd. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $109.56.

Edwards Lifesciences Stock Down 0.0%

EW stock opened at $105.79 on Friday. The stock’s 50 day simple moving average is $90.07 and its 200 day simple moving average is $86.20. Edwards Lifesciences Corporation has a fifty-two week low of $74.66 and a fifty-two week high of $106.80. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.86 and a current ratio of 4.60. The company has a market cap of $60.83 billion, a P/E ratio of 59.77, a price-to-earnings-growth ratio of 2.82 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The firm had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.68 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. On average, research analysts expect that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.